PDF(Pubmed)
Abstract：
BACKGROUND: The Viabahn endoprosthesis has become a vital option for endovascular therapy, yet there is limited long-term data on its effectiveness for peripheral aneurysm repair. This study aimed to evaluate the safety, technical and clinical success, and long-term patency of the Viabahn endoprosthesis for treating femoropopliteal aneurysms.
METHODS: This retrospective tertiary single-center study analyzed patients who underwent a Viabahn endoprosthesis procedure for femoropopliteal aneurysm repair from 2010 to 2020. Intraoperative complications, technical and clinical success rates, and major adverse events (MAE, including acute thrombotic occlusion, major amputation, myocardial infarction, and device- or procedure-related death) at 30 days were assessed. Incidence of clinically-driven target lesion revascularisation (cdTLR) was noted. Patency rates were evaluated by Kaplan-Meier analysis.
RESULTS: Among 19 patients (mean age, 72 ± 12 years; 18 male, 1 female) who underwent aneurysm repair using the Viabahn endoprosthesis, there were no intraoperative adverse events, with 100% technical and clinical success rates. At the 30-day mark, all patients (19/19, 100%) were free of MAE. The median follow-up duration was 1,009 days [IQR, 462-1,466]. Popliteal stent graft occlusion occurred in 2/19 patients (10.5%) after 27 and 45 months, respectively. Consequently, the primary patency rates were 100%, 90%, 74% at 12, 24, and 36-72 months, respectively. Endovascular cdTLR was successful in both cases, resulting in sustained secondary patency at 100%.
CONCLUSIONS: The use of Viabahn endoprostheses for femoropopliteal aneurysm repair demonstrated technical and clinical success rates of 100%, a 0% 30-day MAE rate, and excellent long-term patency.
METHODS: This retrospective tertiary single-center study analyzed patients who underwent a Viabahn endoprosthesis procedure for femoropopliteal aneurysm repair from 2010 to 2020. Intraoperative complications, technical and clinical success rates, and major adverse events (MAE, including acute thrombotic occlusion, major amputation, myocardial infarction, and device- or procedure-related death) at 30 days were assessed. Incidence of clinically-driven target lesion revascularisation (cdTLR) was noted. Patency rates were evaluated by Kaplan-Meier analysis.
RESULTS: Among 19 patients (mean age, 72 ± 12 years; 18 male, 1 female) who underwent aneurysm repair using the Viabahn endoprosthesis, there were no intraoperative adverse events, with 100% technical and clinical success rates. At the 30-day mark, all patients (19/19, 100%) were free of MAE. The median follow-up duration was 1,009 days [IQR, 462-1,466]. Popliteal stent graft occlusion occurred in 2/19 patients (10.5%) after 27 and 45 months, respectively. Consequently, the primary patency rates were 100%, 90%, 74% at 12, 24, and 36-72 months, respectively. Endovascular cdTLR was successful in both cases, resulting in sustained secondary patency at 100%.
CONCLUSIONS: The use of Viabahn endoprostheses for femoropopliteal aneurysm repair demonstrated technical and clinical success rates of 100%, a 0% 30-day MAE rate, and excellent long-term patency.
摘要：
背景：Viabahn内置假体已成为血管内治疗的重要选择，然而,关于其对周围动脉瘤修复的有效性的长期数据有限.本研究旨在评估安全性，技术和临床成功，以及Viabahn内置假体的长期通畅性，用于治疗股动脉动脉瘤。
方法：这项回顾性的第三级单中心研究分析了从2010年到2020年接受Viabahn内修复股pop动脉瘤手术的患者。术中并发症,技术和临床成功率，和主要不良事件(MAE，包括急性血栓性闭塞,严重截肢,心肌梗塞,和设备或手术相关的死亡）在30天进行评估。注意到临床驱动的靶病变血运重建（cdTLR）的发生率。通畅率通过Kaplan-Meier分析进行评估。
结果：在19例患者中（平均年龄，72±12岁；18名男性，1名女性）使用Viabahn内置假体进行动脉瘤修复，术中无不良事件,100%的技术和临床成功率。在30天大关，所有患者（19/19，100%）均无MAE。中位随访时间为1,009天[IQR，462-1,466]。2/19例(10.5%)患者在27个月和45个月后发生髌骨支架植入术闭塞,分别。因此,主要通畅率为100%，90%,在12、24和36-72个月时为74％，分别。血管内cdTLR在两种情况下都是成功的，导致100%的持续二次通畅。
结论：使用Viabahn假体修复股pop动脉瘤的技术和临床成功率为100％，0%的30天MAE利率，和出色的长期通畅性。
方法：这项回顾性的第三级单中心研究分析了从2010年到2020年接受Viabahn内修复股pop动脉瘤手术的患者。术中并发症,技术和临床成功率，和主要不良事件(MAE，包括急性血栓性闭塞,严重截肢,心肌梗塞,和设备或手术相关的死亡）在30天进行评估。注意到临床驱动的靶病变血运重建（cdTLR）的发生率。通畅率通过Kaplan-Meier分析进行评估。
结果：在19例患者中（平均年龄，72±12岁；18名男性，1名女性）使用Viabahn内置假体进行动脉瘤修复，术中无不良事件,100%的技术和临床成功率。在30天大关，所有患者（19/19，100%）均无MAE。中位随访时间为1,009天[IQR，462-1,466]。2/19例(10.5%)患者在27个月和45个月后发生髌骨支架植入术闭塞,分别。因此,主要通畅率为100%，90%,在12、24和36-72个月时为74％，分别。血管内cdTLR在两种情况下都是成功的，导致100%的持续二次通畅。
结论：使用Viabahn假体修复股pop动脉瘤的技术和临床成功率为100％，0%的30天MAE利率，和出色的长期通畅性。
